People with allergic rhinitis (AR) who are not controlled on conventional therapy can be treated using allergy immunotherapy (AIT) administered as tablets, injections or drops. In the US, the use of sublingual immunotherapy as tablets (SLIT-tablets) is limited in comparison to subcutaneous immunotherapy (SCIT). This study investigated patients’ preference for SLIT-tablets vs monthly or weekly SCIT from a US patient perspective. Read the publication: https://www.dovepress.com/preference-for-immunotherapy-with-tablets-by-people-with-allergic-rhin-peer-reviewed-fulltext-article-PPA